<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Centre for Infection &amp; Immunity</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D231ECC5-D117-4E74-87D7-C1B672E3CB12"><gtr:id>D231ECC5-D117-4E74-87D7-C1B672E3CB12</gtr:id><gtr:firstName>Cecilia</gtr:firstName><gtr:surname>O Kane</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/196A7E43-E653-4989-82D1-8C8054CCD508"><gtr:id>196A7E43-E653-4989-82D1-8C8054CCD508</gtr:id><gtr:firstName>Danny</gtr:firstName><gtr:surname>McAuley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53330BD4-5F13-42A3-88E4-C02398FF5B47"><gtr:id>53330BD4-5F13-42A3-88E4-C02398FF5B47</gtr:id><gtr:firstName>Clifford</gtr:firstName><gtr:surname>Taggart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701690"><gtr:id>A5F1ADE9-2C51-4CD0-A74C-22C18A282AC9</gtr:id><gtr:title>Keratinocyte growth factor as a novel treatment in an in vivo human endotoxaemic model of lung injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701690</gtr:grantReference><gtr:abstractText>In many severe illnesses, such as pneumonia or following a road traffic accident, people develop acute lung problems. For reasons that are unclear, their lungs fail and fill with water making breathing difficult and they require support in an intensive care unit. This is termed ?acute lung injury? (ALI). There is no effective treatment for ALI.
The reason the lung fails involves damage to the delicate lining of cells that allow oxygen to pass into the body. This lining is called the alveolar epithelium. A protein called keratinocyte growth factor (KGF) improves lung repair by increasing the number of lining cells and helping them move to damaged parts of the lung. Humans produce KGF, however, patients who have ALI do not have enough and repair is inadequate.
This study will investigate if additional KGF helps lung repair in an established clinical model of ALI.
If effective, results of this study will lead to a clinical trial of this novel therapy in the prevention and treatment of ALI. This project will also provide new information about mechanisms in the development of ALI which could lead to new therapeutic targets.</gtr:abstractText><gtr:technicalSummary>Acute lung injury (ALI) is a common devastating clinical syndrome. ALI occurs in response to a variety of insults, such as trauma and severe pneumonia, and mortality is approximately 50%. ALI is associated with neutrophil activation with the release of cytokines and proteases. The resulting inflammatory damage to the alveolar epithelial and capillary endothelial barrier is central to the severity of lung injury causing pulmonary oedema and acute respiratory failure with the need for mechanical ventilation.
Proliferation of alveolar type II epithelial cells is critical to the restoration of alveolar architecture and recovery from ALI. Keratinocyte growth factor (KGF) specifically promotes epithelial proliferation. In addition, KGF promotes epithelial migration, differentiation and re-epithelialisation of wounds. KGF also downregulates pro-inflammatory cytokines and enhances endothelial cell resistance to injury. In animal models of ALI, KGF reduces alveolar capillary permeability, pulmonary oedema and improves mortality. Despite the therapeutic potential no human studies have investigated the effect of exogenous KGF in ALI. Palifermin is recombinant human KGF, and has biological activity analogous to the native protein. Palifermin is safe and is used clinically for treatment of oral mucositis; associated with chemo- and/or radio- therapy. This study will investigate in vivo if palifermin modulates mechanisms important in alveolar epithelial injury and repair in a safe and validated model of lung injury induced by inhalation of low dose lipopolysaccharide (LPS) in healthy volunteers.
Hypothesis: Treatment with palifermin will decrease lung injury induced by LPS inhalation in humans.
The specific aims of this study are to assess the ability of KGF to attenuate lung injury by measuring
1) alveolar and plasma inflammatory response
2) alveolar epithelial and endothelial function
3) alveolar matrix metalloproteinase activity
4) intracellular signalling and transcription factor activation in the alveolar space
This will be a prospective, randomised, double blind, placebo controlled clinical trial.
Subjects will be randomised to palifermin 60microg/kg or placebo intravenously for 3 days prior to LPS inhalation. The dose and duration of pre-treatment was determined on the basis of experimental and clinical data, and is the normal therapeutic dose for treatment of oral mucositis.
These experiments will represent the first study of exogenous KGF in a human model of ALI and will provide new understanding of the mechanisms by which KGF modulates alveolar injury. If effective this study will inform subsequent clinical trials of KGF in ALI.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>246627</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine Edinburgh</gtr:department><gtr:description>Monocyte depletion</gtr:description><gtr:id>A2695891-2F74-47AA-8366-1AACB4C09A38</gtr:id><gtr:impact>Successful grant application to Jules Thorn Trust
Paper in press with European Respiratory Journal</gtr:impact><gtr:outcomeId>VUoUH8FkxkA-1</gtr:outcomeId><gtr:piContribution>Provided expertise to establish the inhaled LPS model of ALi</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Translational Pharmacology &amp; Discovery Medicine</gtr:department><gtr:description>GSK</gtr:description><gtr:id>02885FE2-EC3F-4C76-AE04-E0BBB39A0FFB</gtr:id><gtr:impact>MRC Proximity to Discovery award, &amp;pound;15,600, 2016
Accelerating the discovery and development of new medicines for the treatment of Acute Respiratory Distress Syndrome (ARDS) through knowledge exchange
PhD studentship with GSK to investigate mechanisms of pulmonary oedema formation in ARDS
GSK funding to undertake pre-clinical study to to investigate role of Tregs in ARDS</gtr:impact><gtr:outcomeId>VBkqfNeU3WB-1</gtr:outcomeId><gtr:partnerContribution>Access to novel molecules to test in models of ALI</gtr:partnerContribution><gtr:piContribution>Involved in the design of and undertaking research programme to test novel molecules to test in models of ALI</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>462200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant (MSC)</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L017229/1</gtr:fundingRef><gtr:id>08D33CF0-0F3E-4CDF-BBF7-54B71E1E19E9</gtr:id><gtr:outcomeId>54627dd843a321.23661065</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>196000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Department of Health Social Services and Public Safety (DHSSPS)</gtr:fundingOrg><gtr:id>0CC31DE9-18BD-4537-9C63-5CE4B7D647AB</gtr:id><gtr:outcomeId>VSdGnmvcca50</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Proximity to Discovery</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6FB9A043-47FE-4E73-9167-E3947564326D</gtr:id><gtr:outcomeId>56de327b4de2a9.56616815</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Respiratory Research GSK</gtr:department><gtr:description>GSK</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>C443DD6F-DF26-4DE7-9435-1D556EE8BB14</gtr:id><gtr:outcomeId>58c92cce497bb0.72580085</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>504000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Pathway Funding</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J014680/1</gtr:fundingRef><gtr:id>2E9E799D-F57B-43A5-81E6-3DD1597B9933</gtr:id><gtr:outcomeId>TPcvm5NXYob</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Keratinocyte growth factor (KGF) was tested in this model of ALI and is now being tested in a phase 2 trial in patients with ALI. Funded by HSC Research and Development Division</gtr:description><gtr:id>C5296CB5-DD1B-4712-8B4C-8BEBF8388EA7</gtr:id><gtr:impact>Informed the design of an ongoing phase 2 trial in patients with ALI.</gtr:impact><gtr:outcomeId>iPfSMDvdqF3</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>KGF in LPS model</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Aspirin was tested in this model of ALI and is now being tested in a phase 2 trial in patients with ALI.</gtr:description><gtr:id>9CBF7598-63F3-48BB-AE68-D99B5C7CBAC4</gtr:id><gtr:impact>Informed the design of an ongoing phase 2 trial in patients with ALI (STAR).</gtr:impact><gtr:outcomeId>54628ef33e61b7.90621186</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ARENA</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Selective TNFR1 antagonism as tested in the LPS model of ALI and is now being tested in a phase 2 trial in patients at risk of ALI.</gtr:description><gtr:id>8A90A583-693B-4F2D-9114-1F53D706F7C2</gtr:id><gtr:impact>Informed the design of a planned phase 2 trial in patients at risk of ALI.</gtr:impact><gtr:outcomeId>546296f15617a6.59346697</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Selective TNFR1 antagonism in ARDS</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Prospective randomised double-blind placebo-controlled phase II single centre trial of Keratinocyte growth factor in acute lung injury which is ongoing. Funded by NI HSC Research and Development Division.</gtr:description><gtr:id>74FD5F48-7A49-48A5-B4EC-DE1458D87C82</gtr:id><gtr:impact>Phase 2 trial in patients with ARDS has been completed.</gtr:impact><gtr:outcomeId>MDsoAeSTNX4</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>KARE</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients Undergoing Oesophagectomy Surgery</gtr:description><gtr:id>B48F2BD1-3043-4170-AB63-E07B021BA19B</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>54629ac2a68447.71239788</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Selective TNFR1 antagonism to prevent ARDS</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Provided expertise to establish the LPS model of ALI at the University of Edinburgh and in a clinical research organisation called Celerion</gtr:description><gtr:id>D35F1FE9-8FFA-4B4C-9E89-D5D279F3136E</gtr:id><gtr:impact>Successful grant application to Jules Thorn Trust
Ongoing collaboration with GSK</gtr:impact><gtr:outcomeId>T8VeKgH5r1m</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>LPS model</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5AEC82A2-5619-4D3F-8E40-F60F178A0E30</gtr:id><gtr:title>Human models of acute lung injury.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed409b235bc0ccd8454c9ad343b40ee"><gtr:id>eed409b235bc0ccd8454c9ad343b40ee</gtr:id><gtr:otherNames>Proudfoot AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_12580_20_21357760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA593927-99CD-42FB-B187-2D5689CCC401</gtr:id><gtr:title>Is there a need for emerging drugs for the acute respiratory distress syndrome?</gtr:title><gtr:parentPublicationTitle>Expert opinion on emerging drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf3c6c2858661f2eb4de7dc6119444d"><gtr:id>acf3c6c2858661f2eb4de7dc6119444d</gtr:id><gtr:otherNames>Fitzgerald M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-8214</gtr:issn><gtr:outcomeId>5462729006da04.33151482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D11BF1A4-89D2-454E-BA86-EB75E3C673F7</gtr:id><gtr:title>Acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17671420ae54897b6ad7c56308487e3"><gtr:id>a17671420ae54897b6ad7c56308487e3</gtr:id><gtr:otherNames>Sweeney RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58c44f99af7531.25547575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B48223D0-A342-4370-806C-3C7B357BA8D5</gtr:id><gtr:title>Pharmacological treatments in ARDS; a state-of-the-art update.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efd8e5d7249c011b0f94d537e2b24e5a"><gtr:id>efd8e5d7249c011b0f94d537e2b24e5a</gtr:id><gtr:otherNames>Boyle AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_12580_20_23957905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3EEE190-1236-4764-B054-4327472B09BD</gtr:id><gtr:title>Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury.</gtr:title><gtr:parentPublicationTitle>Critical care clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7df1ed9b6b436ed7d7746c319acb5313"><gtr:id>7df1ed9b6b436ed7d7746c319acb5313</gtr:id><gtr:otherNames>Cross LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0749-0704</gtr:issn><gtr:outcomeId>pm_27241_21_21440206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD4FAE18-11BE-4265-BC65-28BC765A781D</gtr:id><gtr:title>Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae21e9c1839a8b5535f2713c32c95fec"><gtr:id>ae21e9c1839a8b5535f2713c32c95fec</gtr:id><gtr:otherNames>McAuley DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn><gtr:outcomeId>5462728f5763f7.13657468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F239918-A4B2-46C0-A277-1D453DCC7B33</gtr:id><gtr:title>Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57f812c9c4e876799f448057e9bddbc9"><gtr:id>57f812c9c4e876799f448057e9bddbc9</gtr:id><gtr:otherNames>Shyamsundar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5462728faa3b58.26273009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A36BC91E-FEB9-46A7-83E4-0059CE990A7A</gtr:id><gtr:title>A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc797cd3a172aa8fe324b25328d15fb5"><gtr:id>dc797cd3a172aa8fe324b25328d15fb5</gtr:id><gtr:otherNames>Barr LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_12580_20_23627345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3981D99E-51A6-4492-ACC1-882A529B5757</gtr:id><gtr:title>Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction--a randomised placebo-controlled trial (KARE): study protocol.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7df1ed9b6b436ed7d7746c319acb5313"><gtr:id>7df1ed9b6b436ed7d7746c319acb5313</gtr:id><gtr:otherNames>Cross LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_12580_20_23419093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B11B5891-5978-4FBB-B044-FB2415687C82</gtr:id><gtr:title>A novel subpopulation of monocyte-like cells in the human lung after lipopolysaccharide inhalation.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2829c4cc11fbdc037ce0c865e466528"><gtr:id>a2829c4cc11fbdc037ce0c865e466528</gtr:id><gtr:otherNames>Brittan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_12580_20_22267753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BB1A534-CE53-447F-AC0C-5747DFB39F0C</gtr:id><gtr:title>Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b58401b0d369467a5ead6f7b853f21ec"><gtr:id>b58401b0d369467a5ead6f7b853f21ec</gtr:id><gtr:otherNames>Asmussen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5462728fd43798.49115006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D115EBF4-DB0B-47D9-B42E-F17185D4C601</gtr:id><gtr:title>Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1cb2ed5d3d9879c33e75413e0566c3b6"><gtr:id>1cb2ed5d3d9879c33e75413e0566c3b6</gtr:id><gtr:otherNames>Proudfoot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a99b82b1e37f3.77036294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>532A094F-32B7-42A8-9A4C-1297BCCB2709</gtr:id><gtr:title>Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ea40a259615b044d63ae44948aa642a"><gtr:id>5ea40a259615b044d63ae44948aa642a</gtr:id><gtr:otherNames>Finch PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn><gtr:outcomeId>pm_12580_20_24151975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26CDF4E1-DF6A-4212-85A6-7F7D8167483D</gtr:id><gtr:title>Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae21e9c1839a8b5535f2713c32c95fec"><gtr:id>ae21e9c1839a8b5535f2713c32c95fec</gtr:id><gtr:otherNames>McAuley DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a99b6a8389365.46611559</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701690</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>